Compound Profiles
GLP-1 Receptor Agonists: A Research Overview of Semaglutide, Tirzepatide & Retatrutide
Healthy Aminos Research Team · · 8 min read
The GLP-1 Pathway
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 receptor agonists bind to the GLP-1R, a class B G-protein coupled receptor expressed in pancreatic beta cells, the central nervous system, and other tissues.
Research interest in GLP-1 receptor agonists has expanded significantly following multiple large-scale clinical trial programs.
Semaglutide
Semaglutide is a 31-amino acid GLP-1 receptor agonist with two key structural modifications: an Aib substitution at position 8 (protecting against DPP-4 degradation) and a C-18 fatty diacid linker at position 26 (enabling albumin binding for half-life extension to approximately 7 days).
Published data from the SUSTAIN, PIONEER, and STEP trial programs — involving over 20,000 participants — have been extensively documented in peer-reviewed journals.
Tirzepatide
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist. Its mechanism engages both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. Published data from the SURPASS and SURMOUNT programs have documented dose-dependent responses across metabolic parameters.
The SURPASS-2 trial represents the only head-to-head comparison with semaglutide published to date.
Retatrutide
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Early phase clinical results published in the New England Journal of Medicine showed dose-dependent metabolic responses. The glucagon receptor component adds thermogenic and lipolytic signaling pathways not present in GLP-1-only or dual-agonist compounds.
Molecular Comparison
All three compounds share the fundamental GLP-1R agonist mechanism but differ in receptor selectivity profile, fatty acid modifications for half-life extension, and the number of receptor targets engaged.